-
Takuya Matsunaga,
Kiyoshi Yamashita,
Yoko Kubuki,
Takanori Toyama,
Osamu Imataki,
Kouichi Maeda,
Noriaki Kawano,
Seiichi Satou,
Hiroshi Kawano,
Junzo Ishizaki, [......],
Keiko Katayose,
Haruko K-Shimoda,
Kotaro Shide, Shojiro Yamamoto,
Hiroshi Moritake,
Hiroyuki Nunoi,
Shigeyoshi Makino,
Akira Kitanaka,
Hitoshi Matsuoka,
Kazuya Shimoda
[show abstract]
[hide abstract]
ABSTRACT: We performed a retrospective population-based cohort study of acute myeloid leukemia (AML) in Miyazaki Prefecture, Japan. Over 6 years, we diagnosed 221 patients (211 adults and 10 children) with AML, indicating an incidence of AML in Miyazaki Prefecture of 3.2 per 100,000 per year. In 193 adult patients with non-acute promyelocytic leukemia (APL), the proportion of patients with myelodysplasia, unfavorable risk karyotypes, antecedent hematologic diseases, prior chemotherapy for other malignancies, and small proportion of blasts in the marrow was higher in patients ≥65 years, and patients with poor performance status (PS) and higher WBC counts at diagnosis were more prevalent among patients ≥75 years. One-third of the adult non-APL patients met the inclusion criteria usually applied in clinical trials: de novo AML, age ≤64 years with PS 0-2 and no key organ dysfunction. The 5-year overall survival (OS) rate of adult non-APL patients was 21.1 % (patients ≤64 years, 33.8 %; 65-74 years, 21.6 %; ≥75 years, 0 %). Multivariate analysis revealed that French-American-British subtypes M0, M6, and M7, poor PS (3, 4), unfavorable risk karyotypes, and higher WBC counts at diagnosis were independent adverse prognostic factors associated with OS. This analysis provides real world data.
International journal of hematology 07/2012; 96(3):342-9. · 1.17 Impact Factor
-
Makoto Naganuma,
Reiko Kunisaki,
Naoki Yoshimura,
Masakazu Nagahori,
Hisae Yamamoto,
Hideaki Kimura,
Minako Sako,
Takaaki Kawaguchi,
Masakazu Takazoe, Shojiro Yamamoto,
Toshiyuki Matsui,
Toshifumi Hibi,
Mamoru Watanabe
[show abstract]
[hide abstract]
ABSTRACT: Neither conceptions and pregnancy outcomes nor the safety of medications for childbearing inflammatory bowel disease (IBD) patients has been investigated in Asia. The aim of this study is to analyse conception and pregnancy outcomes of Japanese female IBD patients.
We conducted a retrospective cohort study of pregnant IBD patients at 6 institutions. The incidences of abortion, Caesarean delivery, low birth weight (LBW) (<2500g), and congenital malformation were analysed in these patients. Risk factors associated with adverse outcomes in IBD patients were also assessed.
A total of 325 patients experienced 534 conceptions. Among these, 303 conceptions (57%) were observed during/after disease onset. Although conceptions and pregnancy outcomes after disease onset were comparable to the observed levels prior to disease onset in UC patients, the incidences of spontaneous abortion (OR 5.3; 95%CI 1.1-25.0) and Caesarean delivery (OR 4.8; 95%CI 1.5-15.0) were significantly higher in Crohn's disease (CD) patients whose conceptions occurred after disease onset compared to CD patients whose conceptions occurred before disease onset. The incidences of spontaneous abortion, LBW, and Caesarean delivery were higher in CD patients who had a history of surgery for perianal lesions than in those who did not have perianal lesions or who had ulcerative colitis (UC). In the IBD patients studied after disease onset, independent risk factors for spontaneous abortions included a history of previous treatment for sterility (OR 2.9; 95%CI 1.2-7.0). Independent risk factors for Caesarean operation (OR 4.1, 95% CI: 1.7-10.1) and LBW (OR 3.5, 95% CI: 1.3-9.1) included a history of bowel resection for the treatment of IBD. Congenital malformation was not associated with the factors of type of disease, smoking, and previous surgery.
In Japanese UC patients, conception and pregnancy outcomes after disease onset were comparable to the outcomes observed prior to disease onset, whereas CD appeared to be associated with adverse outcomes. Caesarean operation and LBW were more frequently observed in CD patients who had a history of surgery for perianal lesions and bowel resection.
Journal of Crohn s and Colitis 09/2011; 5(4):317-23. · 2.57 Impact Factor
-
Tadashi Miike,
Yoshihiro Tahara,
Yumi Yamaguchi,
Taku Harada,
Hiroo Abe,
Kazunori Kusumoto,
Masatsugu Numata,
Satoru Hasuike, Shojiro Yamamoto,
Mayumi Kodama,
Kenji Nagata,
Katsuhiro Hayashi,
Kazuya Shimoda
[show abstract]
[hide abstract]
ABSTRACT: A 66-year-old man patient with chronic hepatitis (CH) C and complications from ulcerative colitis (UC) was treated with interferon-beta (IFN-beta). Endoscopically, the UC disease activity was moderate before IFN-beta treatment but was in remission eight week after treatment. However, a few months after stopping IFN treatment, endoscopy revealed that the UC disease activity had returned to moderate levels. This result shows that UC improved with IFN treatment.
Nippon Shokakibyo Gakkai zasshi The Japanese journal of gastro-enterology 10/2008; 105(9):1362-6.
-
Takayuki Matsumoto,
Mitsuo Iida,
Satoshi Motoya,
Ken Haruma,
Yasuo Suzuki,
Kiyonori Kobayashi,
Hiroaki Ito,
Mitsuki Miyata,
Masato Kusunoki,
Tsutomu Chiba, Shojiro Yamamoto,
Toshifumi Hibi
[show abstract]
[hide abstract]
ABSTRACT: This study was designed to evaluate the efficacy of infliximab in patients with Crohn's disease of durations less than one year.
Two nationwide surveys of 35 Japanese institutions majoring in inflammatory bowel disease identified 41 patients with active Crohn's disease who were treated by infliximab within 12 months after the diagnosis (E-group) and 97 patients treated later during their clinical course (L-group). Clinical features, responses to infliximab, and accompanying medications were compared between the two groups. A decrease in Crohn's disease activity index > or = 70 or the index < 150 two weeks after infliximab was regarded to be efficacious.
The age was younger (24 vs. 33 years, median, P < 0.0001) and intestinal stricture (12 vs. 49 percent, P < 0.0001), internal fistula (0 vs. 26 percent, P = 0.0003), and previous intestinal resection (7 vs. 57 percent, P < 0.0001) were less frequent in the E-group than in the L-group. The efficacy of infliximab was different between the two groups with a significantly higher value in the E-group than in the L-group (90 vs. 61 percent, P = 0.0012). A multivariate logistic regression analysis revealed nonstricturing intestinal lesion to be a significant factor related to the efficacy of infliximab.
Infliximab is more efficacious in Crohn's disease with short duration, probably because of less frequent stenosis.
Diseases of the Colon & Rectum 07/2008; 51(6):916-23. · 3.13 Impact Factor
-
Yoshihiro Fukuda,
Masakazu Takazoe,
Akira Sugita,
Tadashi Kosaka,
Fukunori Kinjo,
Yoshimasa Otani,
Hisao Fujii,
Kazutaka Koganei,
Kazuya Makiyama,
Toshio Nakamura, [......], Shojiro Yamamoto,
Toshifumi Ashida,
Akira Majima,
Norikazu Morita,
Kazunari Murakami,
Nobuhide Oshitani,
Kazuya Takahama,
Masahiro Tochihara,
Tomoyuki Tsujikawa,
Makoto Watanabe
[show abstract]
[hide abstract]
ABSTRACT: Anal fistulas are common in individuals with Crohn's disease (CD). We sought to evaluate the efficacy of oral spherical adsorptive carbon (AST-120) (Kremezin; Kureha Corporation, Tokyo, Japan) for the treatment of intractable anal fistulas in patients with CD.
In this multicenter, randomized, double-blind, placebo-controlled trial, patients with CD and at least one active anal fistula under treatment were assigned to receive either AST-120 or placebo for 8 wk. Improvement was defined as a reduction of 50% or more from baseline in the number of draining fistulas observed at both 4 and 8 wk. Remission was defined by closure of all draining fistulas at both 4 and 8 wk. The Perianal Disease Activity Index (PDAI) and Crohn's Disease Activity Index (CDAI) were also assessed.
In total, 62 patients were randomized, of whom 57 received AST-120 (N = 27) or placebo (N = 30). The improvement rate in the AST-120 group (37.0%) was significantly greater than that in the placebo group (10.0%) (P= 0.025). The corresponding remission rates were 29.6% and 6.7%, respectively (P= 0.035). PDAI significantly improved at both 4 and 8 wk with AST-120, compared to placebo (P= 0.004 and P= 0.005, respectively). CDAI was also significantly improved at both 4 and 8 wk in the AST-120 group, compared to the placebo group (P= 0.007 and P= 0.001, respectively). AST-120 treatment was well tolerated and no life-threatening adverse events were observed.
AST-120 is useful for the control of intractable anal fistulas in CD patients.
The American Journal of Gastroenterology 07/2008; 103(7):1721-9. · 7.28 Impact Factor
-
Masatsugu Numata,
Akio Ido,
Akihiro Moriuchi,
Ildeok Kim,
Yoshihiro Tahara, Shojiro Yamamoto,
Satoru Hasuike,
Kenji Nagata,
Yoshifumi Miyata,
Hirofumi Uto,
Hirohito Tsubouchi
[show abstract]
[hide abstract]
ABSTRACT: Hepatocyte growth factor (HGF) modulates intestinal epithelial cell proliferation and migration, serving as a critical regulator of intestinal wound healing. The aim of this study was to clarify the effects of administration of recombinant human HGF on colonic mucosal damage in vivo.
Rats were given 7.5 mg of 2,4,6-trinitrobenzene sulfonic acid (TNBS) per rectum on day 0. On day 5, the degree of TNBS-induced colitis was evaluated endoscopically, and rats suffering from large ulcers (occupying more than two thirds of the luminal circumference) were treated with intravenous bolus injections of recombinant human HGF (1.0 mg/kg per day) or phosphate-buffered saline (PBS) for 5 days.
Rats with TNBS-induced colitis given human HGF showed a significant reduction in colonic ulcer coverage and large intestinal shortening compared with those treated with PBS. Administration of recombinant human HGF also stimulated the proliferation of epithelial cells and reduced the inflammatory cell infiltrate. Finally, HGF treatment decreased the myeloperoxidase activity and tumor necrosis factor alpha levels in the TNBS-inflamed colon tissues.
These results indicate that intravenous injection of HGF accelerates colonic mucosal repair and reduces infiltration of inflammatory cells in rats with TNBS-induced colitis and suggest that HGF has the potential to be a new therapeutic modality to promote intestinal mucosal repair in patients with inflammatory bowel disease.
Inflammatory Bowel Diseases 07/2005; 11(6):551-8. · 4.86 Impact Factor
-
Satoru Hasuike,
Katsuhiro Hayashi,
Hiroo Abe,
Hidenori Sasaki,
Hisayoshi Iwakiri, Shojiro Yamamoto,
Junya Kato,
Hirofumi Uto,
Kiyoshi Yamashita,
Takeshi Hori,
Akio Ido,
Hirohito Tsubouchi
Journal of Gastroenterology 02/2004; 39(5):499-500. · 4.16 Impact Factor
-
Shojiro Yamamoto,
Hiroyuki Minami,
Yoshifumi Miyata,
Akihiro Iwamitsu,
Masatsugu Numata,
Hisayoshi Iwakiri,
Hirofumi Uto,
Takeshi Hori,
Akio Ido,
Katsuhiro Hayashi,
Hirohito Tsubouchi
Nippon Shokakibyo Gakkai zasshi The Japanese journal of gastro-enterology 02/2004; 101(1):27-31.
-
[show abstract]
[hide abstract]
ABSTRACT: Hepatocyte growth factor (HGF) modulates intestinal epithelial cell proliferation and migration, serving as a critical regulator of intestinal wound healing. In this study, we examined the effect of administration of recombinant human HGF on colonic mucosal damage in vivo. Acute colitis was induced in rats by feeding with 5% dextran sulfate sodium (DSS) for 7 days, and colitis was subsequently maintained by feeding with 1% DSS. On the 5th day of DSS administration, osmotic pumps releasing recombinant human HGF (200 microg/day) were implanted into the peritoneum of the rats. Continuous intraperitoneal delivery of HGF led to both increased serum human HGF levels and c-Met tyrosine phosphorylation within the colonic mucosa. Compared with mock-treated rats, those administered human HGF showed a reduction in colitis-associated weight loss, large intestinal shortening, and improved colonic erosions. Enhanced epithelial regeneration and cellular proliferation were observed in rats treated with recombinant human HGF. The weights of the liver, kidneys, and spleen were not affected by HGF administration. These results indicate that HGF administration accelerates colonic mucosal repair in rats with DSS-induced colitis and suggest that recombinant human HGF may be a useful therapeutic tool to facilitate intestinal wound healing in patients with ulcerative colitis.
Journal of Pharmacology and Experimental Therapeutics 11/2003; 307(1):146-51. · 3.83 Impact Factor
